D. E. Shaw & Co., Inc. Checkpoint Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $5,638 - $10,289	-5,813 Reduced 35.08%	10,756 $11,000
Q1 2022 May 16, 2022	SELL	$1.53 - $3.25 $155,685 - $330,703	-101,755 Reduced 86.0%	16,569 $29,000
Q4 2021 Feb 14, 2022	BUY	$2.68 - $4.46 $130,499 - $217,175	48,694 Added 69.93%	118,324 $368,000
Q3 2021 Nov 15, 2021	SELL	$2.5 - $3.53 $52,790 - $74,539	-21,116 Reduced 23.27%	69,630 $230,000
Q2 2021 Aug 16, 2021	BUY	$2.36 - $3.2 $214,160 - $290,387	90,746 New	90,746 $268,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $351M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.